[Comment] Talazoparib: a new biomarker-directed therapy in advanced prostate cancer

The clinical management of advanced prostate cancer is changing, with a risiang number of life-extending treatments. Biomarker-directed treatments are increasingly being used to treat metastatic castration-resistant prostate cancer, including using DNA damage response (DDR) aberrations in genes involved in homologous recombination repair (HRR) to select for treatment with poly(ADP-ribose)-polymerase (PARP) inhibitors.

Lascia un commento